Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash & Current Investments (2018 - 2025)

AVITA Medical (RCEL) has disclosed Cash & Current Investments for 5 consecutive years, with $16.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 54.46% year-over-year to $16.3 million, compared with a TTM value of $16.3 million through Dec 2025, down 54.46%, and an annual FY2025 reading of $16.3 million, down 54.46% over the prior year.
  • Cash & Current Investments was $16.3 million for Q4 2025 at AVITA Medical, down from $23.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $84.6 million in Q2 2022 and bottomed at $14.1 million in Q2 2025.
  • Average Cash & Current Investments over 4 years is $54.0 million, with a median of $61.7 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments fell 1.26% in 2023, then plummeted 70.31% in 2025.
  • Year by year, Cash & Current Investments stood at $79.3 million in 2022, then dropped by 1.26% to $78.3 million in 2023, then crashed by 54.19% to $35.9 million in 2024, then plummeted by 54.46% to $16.3 million in 2025.
  • Business Quant data shows Cash & Current Investments for RCEL at $16.3 million in Q4 2025, $23.3 million in Q3 2025, and $14.1 million in Q2 2025.